ARTICLE | Clinical News
ACE-083: Ph II started
January 12, 2017 12:41 AM UTC
Acceleron began a U.S. Phase II trial to evaluate 150, 200 and 250 mg intramuscular ACE-083 given 3 weeks apart for up to 5 doses in patients with muscle weakness in the bicep or tibialis anterior. An...
BCIQ Company Profiles
BCIQ Target Profiles